{"ticker": {"uuid": "e3c6982e-ae5c-4ff3-adc6-34eca37512f0", "symbol": "GIS", "name": "Gilead Sciences, Inc.", "exchange": "GER", "country": "DE", "sector": "Healthcare", "industry": "Drug Manufacturers - General"}, "articles": [{"title": "Noteworthy ETF Outflows: TQQQ, ADI, MRVL, GILD", "summary": "Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the ProShares UltraPro QQQ (Symbol: TQQQ) where we have detected an approximate $156.7 million dollar outflow -- that's a 0.4% decrease week over week (from 506,050,000 to 503,950,000). Among the largest underlying components of TQQQ, in trading today Analog Devices Inc (Symbol: ADI) is up about 0.8%, Marvell Technology Inc (Symbol: MRVL) is up about 4.9%, and Gilead Sciences Inc (Symbol: GILD) is up by about 1%. For a complete list of holdings, visit the TQQQ Holdings ", "url": "https://www.nasdaq.com/articles/noteworthy-etf-outflows-tqqq-adi-mrvl-gild", "source_link": "https://www.nasdaq.com/articles/noteworthy-etf-outflows-tqqq-adi-mrvl-gild", "source_link_is_lookup": false, "source_name": "nasdaq.com", "published_at": "2026-08-13T14:49:26+00:00", "published_display": "13 Aug 2026 14:49", "source_kind": "publisher", "sentiment": "neutral", "sentiment_pct": 53, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.051909, "evidence_share": 3.9, "evidence_share_display": "3.9", "freshness_pct": 95.2, "age_days": 0.1, "influence_label": "Low", "duplicate_count": 1, "topics": ["ETF", "Etfs", "Markets", "Semiconductors", "Share Price", "Shares Outstanding"], "evidence_basis": "", "score_included": true}, {"title": "Why Gilead Sciences (GILD) Is Back In The Spotlight", "summary": "Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Gilead Sciences (GILD) is back in focus after announcing a collaboration with Nucleai that applies AI powered tissue analytics to its antibody drug conjugate programs, with the goal of speeding biomarker discovery across its oncology pipeline. See our latest analysis for Gilead Sciences. At a share price of $135.87, Gilead Sciences has posted an 11.74% year to date share price return and a 16.04% total shareholder return over the past year. Longer term total shareholder retur", "url": "https://finance.yahoo.com/healthcare/articles/why-gilead-sciences-gild-back-091117191.html", "source_link": "https://finance.yahoo.com/healthcare/articles/why-gilead-sciences-gild-back-091117191.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-13T09:11:17+00:00", "published_display": "13 Aug 2026 09:11", "source_kind": "aggregator", "sentiment": "neutral", "sentiment_pct": 46, "tone_signals": ["Positive valuation view", "Negative valuation view"], "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.079585, "evidence_share": 6.0, "evidence_share_display": "6", "freshness_pct": 94.9, "age_days": 0.4, "influence_label": "Low", "duplicate_count": 1, "topics": ["Biopharma", "Dividends", "Earnings", "Oncology", "Share Price", "Share Buyback"], "evidence_basis": "", "score_included": true}, {"title": "5 Must-Read Analyst Questions From Gilead Sciences\u2019s Q2 Earnings Call", "summary": "5 Must-Read Analyst Questions From Gilead Sciences's Q2 Earnings Call Gilead Sciences delivered a solid Q2, with year-over-year sales growth led by strong demand in its HIV franchise, particularly Biktarvy and the PrEP segment, as well as advances in oncology and liver disease. Management credited commercial execution and new product launches\u2014including Trodelvy in breast cancer and Livdelzi in liver disease\u2014for boosting results. CEO Daniel O'Day highlighted, \"Quarterly PrEP sales doubled year-over-year, exceeding $1 billion for the first time,\" underscoring the impact of portfolio expansion. T", "url": "https://finance.yahoo.com/healthcare/articles/5-must-read-analyst-questions-042100262.html", "source_link": "https://finance.yahoo.com/healthcare/articles/5-must-read-analyst-questions-042100262.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-13T04:21:00+00:00", "published_display": "13 Aug 2026 04:21", "source_kind": "aggregator", "sentiment": "positive", "sentiment_pct": 81, "tone_signals": ["Beat expectations", "Guidance raised", "Improving financial comparison", "Deteriorating financial comparison"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.176251, "evidence_share": 13.2, "evidence_share_display": "13.2", "freshness_pct": 92.3, "age_days": 0.6, "influence_label": "Medium", "duplicate_count": 1, "topics": ["Earnings", "Fda Approval", "Guidance", "Hiv", "Oncology", "Revenue Growth"], "evidence_basis": "", "score_included": true}, {"title": "Gilead Sciences (GILD) Expands ADC Research With AI Tissue Analytics", "summary": "Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Gilead Sciences (NasdaqGS:GILD) announced a partnership with Nucleai to use AI-powered tissue analytics in its global antibody drug conjugate programs. The collaboration focuses on translational research to speed up biomarker discovery and support precision oncology development. The AI tools are intended to help standardize and accelerate analysis of tumor samples across Gilead's oncology pipeline. Gilead is not the only company leaning into AI to reshap", "url": "https://finance.yahoo.com/healthcare/articles/gilead-sciences-gild-expands-adc-181350587.html", "source_link": "https://finance.yahoo.com/healthcare/articles/gilead-sciences-gild-expands-adc-181350587.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-12T18:13:50+00:00", "published_display": "12 Aug 2026 18:13", "source_kind": "aggregator", "sentiment": "positive", "sentiment_pct": 69, "tone_signals": ["Operating growth"], "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.141239, "evidence_share": 10.6, "evidence_share_display": "10.6", "freshness_pct": 90.6, "age_days": 1.0, "influence_label": "Medium", "duplicate_count": 2, "topics": ["AI", "BIOTECH", "Biotech", "DRUG-DISCOVERY", "Drug Discovery", "ONCOLOGY"], "evidence_basis": "", "score_included": true}, {"title": "TNGX Stock Dips 5% as Q2 Earnings Miss Estimates on Higher Expenses", "summary": "Tango Therapeutics TNGX incurred a loss of 37 cents per share in the second quarter of 2026, wider than the Zacks Consensus Estimate of a loss of 31 cents. The company had reported a loss of 35 cents per share in the year-ago quarter. Collaboration revenues were zero compared with $3.2 million a year earlier. Tango shares were down 4.8% on Tuesday, likely due to investor disappointment over the earnings miss. Higher operating expenses weighed on the result. TNGX's Q2 Results in Detail In the absence of a marketed product, Tango has no regular source of income. The company instead reports colla", "url": "https://finance.yahoo.com/markets/stocks/articles/tngx-stock-dips-5-q2-144600756.html", "source_link": "https://finance.yahoo.com/markets/stocks/articles/tngx-stock-dips-5-q2-144600756.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-12T14:46:00+00:00", "published_display": "12 Aug 2026 14:46", "source_kind": "aggregator", "sentiment": "negative", "sentiment_pct": 25, "tone_signals": ["Missed expectations"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.188777, "evidence_share": 14.2, "evidence_share_display": "14.2", "freshness_pct": 85.3, "age_days": 1.1, "influence_label": "Medium", "duplicate_count": 2, "topics": ["BIOTECH", "Biotech", "CLINICAL-TRIALS", "Clinical Trials", "EARNINGS", "EARNINGS PER SHARE"], "evidence_basis": "", "score_included": true}, {"title": "3 Healthcare Stocks with Open Questions", "summary": "3 Healthcare Stocks with Open Questions Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only rising as the industry has posted a 22.3% gain over the past six months, beating the S&P 500 by 11.2 percentage points. Regardless of these results, investors must exercise caution as many businesses in this space are subject to heavy regulation that can influence their earnings potential. With that said, here are three healthcare stocks we're steering clear of.", "url": "https://finance.yahoo.com/healthcare/articles/3-healthcare-stocks-open-questions-025322220.html", "source_link": "https://finance.yahoo.com/healthcare/articles/3-healthcare-stocks-open-questions-025322220.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-12T02:53:22+00:00", "published_display": "12 Aug 2026 02:53", "source_kind": "aggregator", "sentiment": "positive", "sentiment_pct": 63, "tone_signals": ["Improving financial comparison", "Margin pressure", "Operating deterioration", "Operating growth"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.150123, "evidence_share": 11.3, "evidence_share_display": "11.3", "freshness_pct": 79.7, "age_days": 1.6, "influence_label": "Medium", "duplicate_count": 2, "topics": ["EARNINGS", "EARNINGS PER SHARE", "Earnings", "Earnings Per Share", "FREE CASH FLOW", "Free Cash Flow"], "evidence_basis": "", "score_included": true}, {"title": "MacroGenics Announces Achievement of $10 Million Milestone Following Gilead\u2019s Exercise of Option to License Preclinical Bispecific Program", "summary": "MacroGenics, Inc. ROCKVILLE, MD, Aug. 11, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that Gilead Sciences, Inc. has exercised its option to obtain an exclusive license for a preclinical bispecific program under the companies' 2022 collaboration agreement. The option exercise triggers a $10 million payment to MacroGenics. The licensed program incorporates MacroGenics' TRIDENT\u00ae platform and is directed against two undisclosed targets", "url": "https://finance.yahoo.com/healthcare/articles/macrogenics-announces-achievement-10-million-200500875.html", "source_link": "https://finance.yahoo.com/healthcare/articles/macrogenics-announces-achievement-10-million-200500875.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-11T20:05:00+00:00", "published_display": "11 Aug 2026 20:05", "source_kind": "aggregator", "sentiment": "neutral", "sentiment_pct": 52, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.030017, "evidence_share": 2.3, "evidence_share_display": "2.3", "freshness_pct": 51.4, "age_days": 1.9, "influence_label": "Low", "duplicate_count": 2, "topics": ["BIOTECH", "Biotech", "CANCER", "Cancer", "LICENSING", "Licensing"], "evidence_basis": "", "score_included": true}, {"title": "J&J Trading Above 200- & 50-Day SMAs: Buy, Sell or Hold the Stock?", "summary": "Johnson & Johnson JNJ stock has been trading above both its 50-day and 200-day simple moving averages (SMAs) since mid-June. Trading above the 200-day SMA indicates that the stock's longer-term trend has turned positive, while staying above the 50-day SMA suggests that shorter-term momentum remains supportive. When a stock trades above both averages, investors generally interpret it as evidence that buying interest is strong enough to keep the shares above their medium- and long-term trend levels.Zacks Investment Research Image Source: Zacks Investment Research This strong share price performa", "url": "https://finance.yahoo.com/markets/stocks/articles/j-j-trading-above-200-131200196.html", "source_link": "https://finance.yahoo.com/markets/stocks/articles/j-j-trading-above-200-131200196.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-11T13:12:00+00:00", "published_display": "11 Aug 2026 13:12", "source_kind": "aggregator", "sentiment": "positive", "sentiment_pct": 78, "tone_signals": ["Operating growth"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.169579, "evidence_share": 12.7, "evidence_share_display": "12.7", "freshness_pct": 73.6, "age_days": 2.2, "influence_label": "Medium", "duplicate_count": 2, "topics": ["EARNINGS", "Earnings", "INNOVATIVE-MEDICINE", "Innovative Medicine", "LITIGATION", "Litigation"], "evidence_basis": "", "score_included": true}, {"title": "The Galien Foundation Announces 2026 Prix Galien USA Nominees for \"Best Biotechnology Product,\" \"Best Pharmaceutical Product,\" and \"Best Product for Rare/Orphan Diseases\"", "summary": "A Milestone 20th Anniversary Edition Recognizing Excellence in Medical Science and Patient Care NEW YORK, Aug. 11, 2026 /PRNewswire/ -- The Galien Foundation, the premier global institution dedicated to honoring innovators in life sciences, today announced the nominees for the 2026 Prix Galien USA Awards in the \"Best Biotechnology Product,\" \"Best Pharmaceutical Product,\" and \"Best Product for Rare/Orphan Diseases\" categories. Winners will be honored at the Prix Galien USA Awards Ceremony on October 29, 2026, at the American Museum of Natural History in New York City.logo \"We are proud to recog", "url": "https://finance.yahoo.com/healthcare/articles/galien-foundation-announces-2026-prix-130000242.html", "source_link": "https://finance.yahoo.com/healthcare/articles/galien-foundation-announces-2026-prix-130000242.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-11T13:00:00+00:00", "published_display": "11 Aug 2026 13:00", "source_kind": "aggregator", "sentiment": "positive", "sentiment_pct": 62, "tone_signals": ["Positive financial language"], "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.081635, "evidence_share": 6.1, "evidence_share_display": "6.1", "freshness_pct": 80.3, "age_days": 2.2, "influence_label": "Low", "duplicate_count": 1, "topics": ["Biotech", "Fda Approval", "Pharmaceuticals", "Rare Diseases"], "evidence_basis": "", "score_included": true}, {"title": "Nucleai Advances AI-Powered Tissue Intelligence Through Large-Scale Oncology ADC Collaboration", "summary": "Collaboration demonstrates how AI-powered Tissue Intelligence is transforming biomarker discovery, translational research, and precision oncology development. TEL AVIV, Israel, August 11, 2026--(BUSINESS WIRE)--Nucleai, a leader in AI-powered Tissue Intelligence, which integrates multimodal tissue image analysis with clinical data to deliver translational insights, today announced an ongoing translational research collaboration with Gilead Sciences supporting its global antibody-drug conjugate (ADC) clinical development programs. As oncology drug development increasingly depends on understandi", "url": "https://finance.yahoo.com/healthcare/articles/nucleai-advances-ai-powered-tissue-130000104.html", "source_link": "https://finance.yahoo.com/healthcare/articles/nucleai-advances-ai-powered-tissue-130000104.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-11T13:00:00+00:00", "published_display": "11 Aug 2026 13:00", "source_kind": "aggregator", "sentiment": "positive", "sentiment_pct": 57, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.030799, "evidence_share": 2.3, "evidence_share_display": "2.3", "freshness_pct": 46.4, "age_days": 2.2, "influence_label": "Low", "duplicate_count": 2, "topics": ["AI Healthcare", "AI-HEALTHCARE", "BIOMARKER-DISCOVERY", "Biomarker Discovery", "PHARMACEUTICAL-COLLABORATION", "PRECISION-ONCOLOGY"], "evidence_basis": "", "score_included": true}, {"title": "Non-Viral Transfection Reagents Market Report (3rd Edition) by Type of Non-Viral Transfection Method, Application Area, End-User & Region, Featuring Bio-Rad, MaxCyte, MilliporeSigma, Thermo Fisher Scientific", "summary": "Company Logo Dublin, Aug. 11, 2026 (GLOBE NEWSWIRE) -- The \"Non-Viral Transfection Reagents Market (3rd Edition) by Type of Non-Viral Transfection Method, Application Area, End-User and Geographical Regions-Trends and Forecast Till 2035\" has been added to ResearchAndMarkets.com's offering. The global non-viral transfection reagents market is projected to increase from USD 0.89 billion in 2026 to USD 2.01 billion by 2035, expanding at a compound annual growth rate of 9.5% during the forecast period. Market growth is being driven by rising demand for nucleic acid-based therapeutics, continued in", "url": "https://finance.yahoo.com/healthcare/articles/non-viral-transfection-reagents-market-084500474.html", "source_link": "https://finance.yahoo.com/healthcare/articles/non-viral-transfection-reagents-market-084500474.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-11T08:45:00+00:00", "published_display": "11 Aug 2026 08:45", "source_kind": "aggregator", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": ["Negative financial language"], "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.056983, "evidence_share": 4.3, "evidence_share_display": "4.3", "freshness_pct": 78.9, "age_days": 2.4, "influence_label": "Low", "duplicate_count": 1, "topics": ["Biotech", "Gene Therapy", "Growth Rate", "Market Research Reports", "Market Research", "Pharmaceuticals"], "evidence_basis": "", "score_included": true}, {"title": "Lakefront Biotherapeutics Reports Half-Year 2026 Financial Results and Provides Business Update", "summary": "Lakefront Biotherapeutics Completed acquisition of Ouro Medicines with Gilead Sciences to advance potential first and best-in-class T-cell engager Forecast at least \u20ac1.6B of cash remaining after funding portfolio to first gamgertamig approval Maintain year-end 2026 cash and financial investments balance guidance of ~\u20ac2B, and now includes \u20ac50M share repurchase Mechelen, Belgium; August 10, 2026, 22.01 CET; regulated information \u2013 Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) today announced its half-year 2026 financial results and provided a second quarter and post-period business upda", "url": "https://finance.yahoo.com/healthcare/articles/lakefront-biotherapeutics-reports-half-2026-200100211.html", "source_link": "https://finance.yahoo.com/healthcare/articles/lakefront-biotherapeutics-reports-half-2026-200100211.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-10T20:01:00+00:00", "published_display": "10 Aug 2026 20:01", "source_kind": "aggregator", "sentiment": "neutral", "sentiment_pct": 54, "tone_signals": [], "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.063305, "evidence_share": 4.7, "evidence_share_display": "4.7", "freshness_pct": 74.9, "age_days": 2.9, "influence_label": "Low", "duplicate_count": 2, "topics": ["BIOTECH", "Biotech", "CLINICAL-TRIALS", "Clinical Trials", "EARNINGS", "Earnings"], "evidence_basis": "", "score_included": true}, {"title": "Key HIV stat over 70% leaves BofA siding with Gilead", "summary": "Gilead Sciences (GILD) closed a strong second quarter, and Wall Street noticed. The drugmaker beat sales expectations across its biggest franchises, raised its full-year outlook, and gave analysts fresh reasons to stay bullish heading into the back half of 2026. Bank of America was one of them. The bank reiterated its Buy rating and kept its $162 price target after the report, well above where the stock trades today. One prevention number in particular caught BofA's attention, and it speaks directly to whether Gilead's next growth engine can last. Why Bank of America is standing by Gilead stoc", "url": "https://finance.yahoo.com/healthcare/articles/key-hiv-stat-over-70-140700040.html", "source_link": "https://finance.yahoo.com/healthcare/articles/key-hiv-stat-over-70-140700040.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-08T14:07:00+00:00", "published_display": "08 Aug 2026 14:07", "source_kind": "aggregator", "sentiment": "positive", "sentiment_pct": 83, "tone_signals": ["Beat expectations", "Guidance raised", "Improving financial comparison", "Contract or approval won"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.106935, "evidence_share": 8.0, "evidence_share_display": "8", "freshness_pct": 48.8, "age_days": 5.2, "influence_label": "Medium", "duplicate_count": 1, "topics": ["Earnings", "Fda Approval", "Hiv Treatment", "Oncology", "Price Target", "Price Target"], "evidence_basis": "", "score_included": true}, {"title": "Planned 3,000-share sale by Gilead (NASDAQ: GILD) shareholder Johanna Mercier", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22Planned+3%2C000-share+sale+by+Gilead+%28NASDAQ%3A+GILD%29+shareholder+Johanna+Mercier%22+%22Stock+Titan%22", "source_link_is_lookup": true, "source_name": "Stock Titan", "published_at": "2026-08-06T10:28:04.997225+00:00", "published_display": "06 Aug 2026 10:28", "source_kind": "publisher", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.003699, "evidence_share": 0.3, "evidence_share_display": "0.3", "freshness_pct": 7.9, "age_days": 7.3, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "Gilead Sciences (GILD) CFO sells 3,000 shares in pre-set 10b5-1 plan", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22Gilead+Sciences+%28GILD%29+CFO+sells+3%2C000+shares+in+pre-set+10b5-1+plan%22+%22Stock+Titan%22", "source_link_is_lookup": true, "source_name": "Stock Titan", "published_at": "2026-08-03T05:29:15.672984+00:00", "published_display": "03 Aug 2026 05:29", "source_kind": "publisher", "sentiment": "negative", "sentiment_pct": 42, "tone_signals": ["Institutional or insider selling"], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.001664, "evidence_share": 0.1, "evidence_share_display": "0.1", "freshness_pct": 2.6, "age_days": 10.5, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "Gilead Sciences (NASDAQ: GILD) exec trades 3,000 shares under 10b5-1 plan", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22Gilead+Sciences+%28NASDAQ%3A+GILD%29+exec+trades+3%2C000+shares+under+10b5-1+plan%22+%22Stock+Titan%22", "source_link_is_lookup": true, "source_name": "Stock Titan", "published_at": "2026-07-30T18:05:24.490652+00:00", "published_display": "30 Jul 2026 18:05", "source_kind": "publisher", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.000365, "evidence_share": 0.0, "evidence_share_display": "<0.1", "freshness_pct": 0.8, "age_days": 14.0, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "GILD|Gilead Sciences Inc|Price:129.310|Chg%:-1.550", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22GILD%7CGilead+Sciences+Inc%7CPrice%3A129.310%7CChg%25%3A-1.550%22+%22TradingKey%22", "source_link_is_lookup": true, "source_name": "TradingKey", "published_at": "2026-07-28T05:17:20.407677+00:00", "published_display": "28 Jul 2026 05:17", "source_kind": "publisher", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.000152, "evidence_share": 0.0, "evidence_share_display": "<0.1", "freshness_pct": 0.3, "age_days": 16.5, "influence_label": "Low", "duplicate_count": 2, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "Gilead (NASDAQ: GILD) CEO sells 15,000 shares under 10b5-1 plan", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22Gilead+%28NASDAQ%3A+GILD%29+CEO+sells+15%2C000+shares+under+10b5-1+plan%22+%22Stock+Titan%22", "source_link_is_lookup": true, "source_name": "Stock Titan", "published_at": "2026-07-18T11:27:12.221412+00:00", "published_display": "18 Jul 2026 11:27", "source_kind": "publisher", "sentiment": "negative", "sentiment_pct": 42, "tone_signals": ["Institutional or insider selling"], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 7e-06, "evidence_share": 0.0, "evidence_share_display": "<0.1", "freshness_pct": 0.0, "age_days": 26.3, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "Gilead Sciences (GILD) CFO sells 3,000 shares in pre-set 10b5-1 trade", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22Gilead+Sciences+%28GILD%29+CFO+sells+3%2C000+shares+in+pre-set+10b5-1+trade%22+%22Stock+Titan%22", "source_link_is_lookup": true, "source_name": "Stock Titan", "published_at": "2026-07-17T15:02:55.013921+00:00", "published_display": "17 Jul 2026 15:02", "source_kind": "publisher", "sentiment": "negative", "sentiment_pct": 42, "tone_signals": ["Institutional or insider selling"], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 5e-06, "evidence_share": 0.0, "evidence_share_display": "<0.1", "freshness_pct": 0.0, "age_days": 27.1, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}], "by_tier": {"direct": [{"title": "Noteworthy ETF Outflows: TQQQ, ADI, MRVL, GILD", "summary": "Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the ProShares UltraPro QQQ (Symbol: TQQQ) where we have detected an approximate $156.7 million dollar outflow -- that's a 0.4% decrease week over week (from 506,050,000 to 503,950,000). Among the largest underlying components of TQQQ, in trading today Analog Devices Inc (Symbol: ADI) is up about 0.8%, Marvell Technology Inc (Symbol: MRVL) is up about 4.9%, and Gilead Sciences Inc (Symbol: GILD) is up by about 1%. For a complete list of holdings, visit the TQQQ Holdings ", "url": "https://www.nasdaq.com/articles/noteworthy-etf-outflows-tqqq-adi-mrvl-gild", "source_link": "https://www.nasdaq.com/articles/noteworthy-etf-outflows-tqqq-adi-mrvl-gild", "source_link_is_lookup": false, "source_name": "nasdaq.com", "published_at": "2026-08-13T14:49:26+00:00", "published_display": "13 Aug 2026 14:49", "provider": "eodhd", "providers": ["eodhd"], "source_names": ["nasdaq.com"], "source_kind": "publisher", "story_key": "1bf83bc90c892913c96d9159dc11f2436f52e3155ab02f2e8fc6269a170353e1", "target_scope": "", "durable_archive": false, "archive_provider": "", "sentiment_origin": "provider_blend", "model_confidence": 0.448, "provider_directional_mass": 0.115, "relevance_score": 0.5625, "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 53, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.051909, "evidence_share": 3.9, "evidence_share_display": "3.9", "freshness_pct": 95.2, "age_days": 0.1, "influence_label": "Low", "duplicate_count": 1, "topics": ["ETF", "Etfs", "Markets", "Semiconductors", "Share Price", "Shares Outstanding"], "evidence_basis": "", "score_included": true}, {"title": "Why Gilead Sciences (GILD) Is Back In The Spotlight", "summary": "Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Gilead Sciences (GILD) is back in focus after announcing a collaboration with Nucleai that applies AI powered tissue analytics to its antibody drug conjugate programs, with the goal of speeding biomarker discovery across its oncology pipeline. See our latest analysis for Gilead Sciences. At a share price of $135.87, Gilead Sciences has posted an 11.74% year to date share price return and a 16.04% total shareholder return over the past year. Longer term total shareholder retur", "url": "https://finance.yahoo.com/healthcare/articles/why-gilead-sciences-gild-back-091117191.html", "source_link": "https://finance.yahoo.com/healthcare/articles/why-gilead-sciences-gild-back-091117191.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-13T09:11:17+00:00", "published_display": "13 Aug 2026 09:11", "provider": "eodhd", "providers": ["eodhd"], "source_names": ["finance.yahoo.com"], "source_kind": "aggregator", "story_key": "79ac6a4212879c1730f4d9d7d98c7f0bb6fab689172f414cdbb637101d7d0624", "target_scope": "", "durable_archive": false, "archive_provider": "", "sentiment_origin": "provider_blend", "model_confidence": 0.642, "provider_directional_mass": 0.1558, "relevance_score": 0.318195, "entity_mapped": true, "sentiment_conflict": 0.356, "sentiment": "neutral", "sentiment_pct": 46, "tone_signals": ["Positive valuation view", "Negative valuation view"], "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.079585, "evidence_share": 6.0, "evidence_share_display": "6", "freshness_pct": 94.9, "age_days": 0.4, "influence_label": "Low", "duplicate_count": 1, "topics": ["Biopharma", "Dividends", "Earnings", "Oncology", "Share Price", "Share Buyback"], "evidence_basis": "", "score_included": true}, {"title": "5 Must-Read Analyst Questions From Gilead Sciences\u2019s Q2 Earnings Call", "summary": "5 Must-Read Analyst Questions From Gilead Sciences's Q2 Earnings Call Gilead Sciences delivered a solid Q2, with year-over-year sales growth led by strong demand in its HIV franchise, particularly Biktarvy and the PrEP segment, as well as advances in oncology and liver disease. Management credited commercial execution and new product launches\u2014including Trodelvy in breast cancer and Livdelzi in liver disease\u2014for boosting results. CEO Daniel O'Day highlighted, \"Quarterly PrEP sales doubled year-over-year, exceeding $1 billion for the first time,\" underscoring the impact of portfolio expansion. T", "url": "https://finance.yahoo.com/healthcare/articles/5-must-read-analyst-questions-042100262.html", "source_link": "https://finance.yahoo.com/healthcare/articles/5-must-read-analyst-questions-042100262.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-13T04:21:00+00:00", "published_display": "13 Aug 2026 04:21", "provider": "eodhd", "providers": ["eodhd"], "source_names": ["finance.yahoo.com"], "source_kind": "aggregator", "story_key": "c9105537991a2410bc7664b3b56579e151726bb5f2cfc3df9682a814d45fcc98", "target_scope": "", "durable_archive": false, "archive_provider": "", "sentiment_origin": "provider_blend", "model_confidence": 0.781, "provider_directional_mass": 0.1768, "relevance_score": 0.35355, "entity_mapped": true, "sentiment_conflict": 0.259, "sentiment": "positive", "sentiment_pct": 81, "tone_signals": ["Beat expectations", "Guidance raised", "Improving financial comparison", "Deteriorating financial comparison"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.176251, "evidence_share": 13.2, "evidence_share_display": "13.2", "freshness_pct": 92.3, "age_days": 0.6, "influence_label": "Medium", "duplicate_count": 1, "topics": ["Earnings", "Fda Approval", "Guidance", "Hiv", "Oncology", "Revenue Growth"], "evidence_basis": "", "score_included": true}, {"title": "Gilead Sciences (GILD) Expands ADC Research With AI Tissue Analytics", "summary": "Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Gilead Sciences (NasdaqGS:GILD) announced a partnership with Nucleai to use AI-powered tissue analytics in its global antibody drug conjugate programs. The collaboration focuses on translational research to speed up biomarker discovery and support precision oncology development. The AI tools are intended to help standardize and accelerate analysis of tumor samples across Gilead's oncology pipeline. Gilead is not the only company leaning into AI to reshap", "url": "https://finance.yahoo.com/healthcare/articles/gilead-sciences-gild-expands-adc-181350587.html", "source_link": "https://finance.yahoo.com/healthcare/articles/gilead-sciences-gild-expands-adc-181350587.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-12T18:13:50+00:00", "published_display": "12 Aug 2026 18:13", "provider": "eodhd", "providers": ["archive", "eodhd"], "source_names": ["finance.yahoo.com"], "source_kind": "aggregator", "story_key": "d9683bb69f74210c4baa0a6b901098dea0f33f985349c2426ac47e1792858586", "target_scope": "", "durable_archive": false, "archive_provider": "", "sentiment_origin": "provider_blend", "model_confidence": 0.59, "provider_directional_mass": 0.119, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "positive", "sentiment_pct": 69, "tone_signals": ["Operating growth"], "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.141239, "evidence_share": 10.6, "evidence_share_display": "10.6", "freshness_pct": 90.6, "age_days": 1.0, "influence_label": "Medium", "duplicate_count": 2, "topics": ["AI", "BIOTECH", "Biotech", "DRUG-DISCOVERY", "Drug Discovery", "ONCOLOGY"], "evidence_basis": "", "score_included": true}, {"title": "TNGX Stock Dips 5% as Q2 Earnings Miss Estimates on Higher Expenses", "summary": "Tango Therapeutics TNGX incurred a loss of 37 cents per share in the second quarter of 2026, wider than the Zacks Consensus Estimate of a loss of 31 cents. The company had reported a loss of 35 cents per share in the year-ago quarter. Collaboration revenues were zero compared with $3.2 million a year earlier. Tango shares were down 4.8% on Tuesday, likely due to investor disappointment over the earnings miss. Higher operating expenses weighed on the result. TNGX's Q2 Results in Detail In the absence of a marketed product, Tango has no regular source of income. The company instead reports colla", "url": "https://finance.yahoo.com/markets/stocks/articles/tngx-stock-dips-5-q2-144600756.html", "source_link": "https://finance.yahoo.com/markets/stocks/articles/tngx-stock-dips-5-q2-144600756.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-12T14:46:00+00:00", "published_display": "12 Aug 2026 14:46", "provider": "eodhd", "providers": ["archive", "eodhd"], "source_names": ["finance.yahoo.com"], "source_kind": "aggregator", "story_key": "de3c374c70e34db2b4d2102009d09c2e0ca567a75389b9edbcb742024ff52e00", "target_scope": "", "durable_archive": false, "archive_provider": "", "sentiment_origin": "provider_blend", "model_confidence": 0.669, "provider_directional_mass": 0.147, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.097, "sentiment": "negative", "sentiment_pct": 25, "tone_signals": ["Missed expectations"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.188777, "evidence_share": 14.2, "evidence_share_display": "14.2", "freshness_pct": 85.3, "age_days": 1.1, "influence_label": "Medium", "duplicate_count": 2, "topics": ["BIOTECH", "Biotech", "CLINICAL-TRIALS", "Clinical Trials", "EARNINGS", "EARNINGS PER SHARE"], "evidence_basis": "", "score_included": true}, {"title": "3 Healthcare Stocks with Open Questions", "summary": "3 Healthcare Stocks with Open Questions Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only rising as the industry has posted a 22.3% gain over the past six months, beating the S&P 500 by 11.2 percentage points. Regardless of these results, investors must exercise caution as many businesses in this space are subject to heavy regulation that can influence their earnings potential. With that said, here are three healthcare stocks we're steering clear of.", "url": "https://finance.yahoo.com/healthcare/articles/3-healthcare-stocks-open-questions-025322220.html", "source_link": "https://finance.yahoo.com/healthcare/articles/3-healthcare-stocks-open-questions-025322220.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-12T02:53:22+00:00", "published_display": "12 Aug 2026 02:53", "provider": "eodhd", "providers": ["archive", "eodhd"], "source_names": ["finance.yahoo.com"], "source_kind": "aggregator", "story_key": "dc2ea09e3fe6360e068c698276bfac729fd82e6bbe5bfb2d096dbc2191977eaf", "target_scope": "", "durable_archive": false, "archive_provider": "", "sentiment_origin": "provider_blend", "model_confidence": 0.719, "provider_directional_mass": 0.184, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.681, "sentiment": "positive", "sentiment_pct": 63, "tone_signals": ["Improving financial comparison", "Margin pressure", "Operating deterioration", "Operating growth"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.150123, "evidence_share": 11.3, "evidence_share_display": "11.3", "freshness_pct": 79.7, "age_days": 1.6, "influence_label": "Medium", "duplicate_count": 2, "topics": ["EARNINGS", "EARNINGS PER SHARE", "Earnings", "Earnings Per Share", "FREE CASH FLOW", "Free Cash Flow"], "evidence_basis": "", "score_included": true}, {"title": "MacroGenics Announces Achievement of $10 Million Milestone Following Gilead\u2019s Exercise of Option to License Preclinical Bispecific Program", "summary": "MacroGenics, Inc. ROCKVILLE, MD, Aug. 11, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that Gilead Sciences, Inc. has exercised its option to obtain an exclusive license for a preclinical bispecific program under the companies' 2022 collaboration agreement. The option exercise triggers a $10 million payment to MacroGenics. The licensed program incorporates MacroGenics' TRIDENT\u00ae platform and is directed against two undisclosed targets", "url": "https://finance.yahoo.com/healthcare/articles/macrogenics-announces-achievement-10-million-200500875.html", "source_link": "https://finance.yahoo.com/healthcare/articles/macrogenics-announces-achievement-10-million-200500875.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-11T20:05:00+00:00", "published_display": "11 Aug 2026 20:05", "provider": "eodhd", "providers": ["archive", "eodhd"], "source_names": ["finance.yahoo.com"], "source_kind": "aggregator", "story_key": "07698914dd0ab4b6d8401b7092b3daec8566eb9bcd6985390a0b092944adf058", "target_scope": "", "durable_archive": false, "archive_provider": "", "sentiment_origin": "provider_blend", "model_confidence": 0.451, "provider_directional_mass": 0.1512, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 52, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.030017, "evidence_share": 2.3, "evidence_share_display": "2.3", "freshness_pct": 51.4, "age_days": 1.9, "influence_label": "Low", "duplicate_count": 2, "topics": ["BIOTECH", "Biotech", "CANCER", "Cancer", "LICENSING", "Licensing"], "evidence_basis": "", "score_included": true}, {"title": "J&J Trading Above 200- & 50-Day SMAs: Buy, Sell or Hold the Stock?", "summary": "Johnson & Johnson JNJ stock has been trading above both its 50-day and 200-day simple moving averages (SMAs) since mid-June. Trading above the 200-day SMA indicates that the stock's longer-term trend has turned positive, while staying above the 50-day SMA suggests that shorter-term momentum remains supportive. When a stock trades above both averages, investors generally interpret it as evidence that buying interest is strong enough to keep the shares above their medium- and long-term trend levels.Zacks Investment Research Image Source: Zacks Investment Research This strong share price performa", "url": "https://finance.yahoo.com/markets/stocks/articles/j-j-trading-above-200-131200196.html", "source_link": "https://finance.yahoo.com/markets/stocks/articles/j-j-trading-above-200-131200196.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-11T13:12:00+00:00", "published_display": "11 Aug 2026 13:12", "provider": "eodhd", "providers": ["archive", "eodhd"], "source_names": ["finance.yahoo.com"], "source_kind": "aggregator", "story_key": "5eb3cb65a1afd2dc0743d89b3879c74fdfa3eb94c6a8bd6ff3878e319fe8cfaa", "target_scope": "", "durable_archive": false, "archive_provider": "", "sentiment_origin": "provider_blend", "model_confidence": 0.664, "provider_directional_mass": 0.194, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.149, "sentiment": "positive", "sentiment_pct": 78, "tone_signals": ["Operating growth"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.169579, "evidence_share": 12.7, "evidence_share_display": "12.7", "freshness_pct": 73.6, "age_days": 2.2, "influence_label": "Medium", "duplicate_count": 2, "topics": ["EARNINGS", "Earnings", "INNOVATIVE-MEDICINE", "Innovative Medicine", "LITIGATION", "Litigation"], "evidence_basis": "", "score_included": true}, {"title": "The Galien Foundation Announces 2026 Prix Galien USA Nominees for \"Best Biotechnology Product,\" \"Best Pharmaceutical Product,\" and \"Best Product for Rare/Orphan Diseases\"", "summary": "A Milestone 20th Anniversary Edition Recognizing Excellence in Medical Science and Patient Care NEW YORK, Aug. 11, 2026 /PRNewswire/ -- The Galien Foundation, the premier global institution dedicated to honoring innovators in life sciences, today announced the nominees for the 2026 Prix Galien USA Awards in the \"Best Biotechnology Product,\" \"Best Pharmaceutical Product,\" and \"Best Product for Rare/Orphan Diseases\" categories. Winners will be honored at the Prix Galien USA Awards Ceremony on October 29, 2026, at the American Museum of Natural History in New York City.logo \"We are proud to recog", "url": "https://finance.yahoo.com/healthcare/articles/galien-foundation-announces-2026-prix-130000242.html", "source_link": "https://finance.yahoo.com/healthcare/articles/galien-foundation-announces-2026-prix-130000242.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-11T13:00:00+00:00", "published_display": "11 Aug 2026 13:00", "provider": "eodhd", "providers": ["eodhd"], "source_names": ["finance.yahoo.com"], "source_kind": "aggregator", "story_key": "52566e8435df13cf73fa9717888920ac2672a0bb56e76834a3490f915476fab8", "target_scope": "", "durable_archive": false, "archive_provider": "", "sentiment_origin": "provider_blend", "model_confidence": 0.497, "provider_directional_mass": 0.156, "relevance_score": 0.367425, "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "positive", "sentiment_pct": 62, "tone_signals": ["Positive financial language"], "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.081635, "evidence_share": 6.1, "evidence_share_display": "6.1", "freshness_pct": 80.3, "age_days": 2.2, "influence_label": "Low", "duplicate_count": 1, "topics": ["Biotech", "Fda Approval", "Pharmaceuticals", "Rare Diseases"], "evidence_basis": "", "score_included": true}, {"title": "Nucleai Advances AI-Powered Tissue Intelligence Through Large-Scale Oncology ADC Collaboration", "summary": "Collaboration demonstrates how AI-powered Tissue Intelligence is transforming biomarker discovery, translational research, and precision oncology development. TEL AVIV, Israel, August 11, 2026--(BUSINESS WIRE)--Nucleai, a leader in AI-powered Tissue Intelligence, which integrates multimodal tissue image analysis with clinical data to deliver translational insights, today announced an ongoing translational research collaboration with Gilead Sciences supporting its global antibody-drug conjugate (ADC) clinical development programs. As oncology drug development increasingly depends on understandi", "url": "https://finance.yahoo.com/healthcare/articles/nucleai-advances-ai-powered-tissue-130000104.html", "source_link": "https://finance.yahoo.com/healthcare/articles/nucleai-advances-ai-powered-tissue-130000104.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-11T13:00:00+00:00", "published_display": "11 Aug 2026 13:00", "provider": "eodhd", "providers": ["archive", "eodhd"], "source_names": ["finance.yahoo.com"], "source_kind": "aggregator", "story_key": "b8b5c6f977a3ac10562a3e638f9e1dec987ff33964d104e33d4c4963b0ac1d40", "target_scope": "", "durable_archive": false, "archive_provider": "", "sentiment_origin": "provider_blend", "model_confidence": 0.448, "provider_directional_mass": 0.119, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "positive", "sentiment_pct": 57, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.030799, "evidence_share": 2.3, "evidence_share_display": "2.3", "freshness_pct": 46.4, "age_days": 2.2, "influence_label": "Low", "duplicate_count": 2, "topics": ["AI Healthcare", "AI-HEALTHCARE", "BIOMARKER-DISCOVERY", "Biomarker Discovery", "PHARMACEUTICAL-COLLABORATION", "PRECISION-ONCOLOGY"], "evidence_basis": "", "score_included": true}, {"title": "Non-Viral Transfection Reagents Market Report (3rd Edition) by Type of Non-Viral Transfection Method, Application Area, End-User & Region, Featuring Bio-Rad, MaxCyte, MilliporeSigma, Thermo Fisher Scientific", "summary": "Company Logo Dublin, Aug. 11, 2026 (GLOBE NEWSWIRE) -- The \"Non-Viral Transfection Reagents Market (3rd Edition) by Type of Non-Viral Transfection Method, Application Area, End-User and Geographical Regions-Trends and Forecast Till 2035\" has been added to ResearchAndMarkets.com's offering. The global non-viral transfection reagents market is projected to increase from USD 0.89 billion in 2026 to USD 2.01 billion by 2035, expanding at a compound annual growth rate of 9.5% during the forecast period. Market growth is being driven by rising demand for nucleic acid-based therapeutics, continued in", "url": "https://finance.yahoo.com/healthcare/articles/non-viral-transfection-reagents-market-084500474.html", "source_link": "https://finance.yahoo.com/healthcare/articles/non-viral-transfection-reagents-market-084500474.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-11T08:45:00+00:00", "published_display": "11 Aug 2026 08:45", "provider": "eodhd", "providers": ["eodhd"], "source_names": ["finance.yahoo.com"], "source_kind": "aggregator", "story_key": "087d578d3f75d830d50d54bbb4f31de98eb6f9576d94fb132b7fae0ab08fa04b", "target_scope": "", "durable_archive": false, "archive_provider": "", "sentiment_origin": "provider_blend", "model_confidence": 0.495, "provider_directional_mass": 0.099, "relevance_score": 0.299997, "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": ["Negative financial language"], "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.056983, "evidence_share": 4.3, "evidence_share_display": "4.3", "freshness_pct": 78.9, "age_days": 2.4, "influence_label": "Low", "duplicate_count": 1, "topics": ["Biotech", "Gene Therapy", "Growth Rate", "Market Research Reports", "Market Research", "Pharmaceuticals"], "evidence_basis": "", "score_included": true}, {"title": "Lakefront Biotherapeutics Reports Half-Year 2026 Financial Results and Provides Business Update", "summary": "Lakefront Biotherapeutics Completed acquisition of Ouro Medicines with Gilead Sciences to advance potential first and best-in-class T-cell engager Forecast at least \u20ac1.6B of cash remaining after funding portfolio to first gamgertamig approval Maintain year-end 2026 cash and financial investments balance guidance of ~\u20ac2B, and now includes \u20ac50M share repurchase Mechelen, Belgium; August 10, 2026, 22.01 CET; regulated information \u2013 Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) today announced its half-year 2026 financial results and provided a second quarter and post-period business upda", "url": "https://finance.yahoo.com/healthcare/articles/lakefront-biotherapeutics-reports-half-2026-200100211.html", "source_link": "https://finance.yahoo.com/healthcare/articles/lakefront-biotherapeutics-reports-half-2026-200100211.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-10T20:01:00+00:00", "published_display": "10 Aug 2026 20:01", "provider": "eodhd", "providers": ["archive", "eodhd"], "source_names": ["finance.yahoo.com"], "source_kind": "aggregator", "story_key": "adf2973fc0df2ccccaa28dfdfb19ac492d2f2868c4a5caabc91d668978a6a132", "target_scope": "", "durable_archive": false, "archive_provider": "", "sentiment_origin": "provider_blend", "model_confidence": 0.447, "provider_directional_mass": 0.106, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 54, "tone_signals": [], "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.063305, "evidence_share": 4.7, "evidence_share_display": "4.7", "freshness_pct": 74.9, "age_days": 2.9, "influence_label": "Low", "duplicate_count": 2, "topics": ["BIOTECH", "Biotech", "CLINICAL-TRIALS", "Clinical Trials", "EARNINGS", "Earnings"], "evidence_basis": "", "score_included": true}, {"title": "Key HIV stat over 70% leaves BofA siding with Gilead", "summary": "Gilead Sciences (GILD) closed a strong second quarter, and Wall Street noticed. The drugmaker beat sales expectations across its biggest franchises, raised its full-year outlook, and gave analysts fresh reasons to stay bullish heading into the back half of 2026. Bank of America was one of them. The bank reiterated its Buy rating and kept its $162 price target after the report, well above where the stock trades today. One prevention number in particular caught BofA's attention, and it speaks directly to whether Gilead's next growth engine can last. Why Bank of America is standing by Gilead stoc", "url": "https://finance.yahoo.com/healthcare/articles/key-hiv-stat-over-70-140700040.html", "source_link": "https://finance.yahoo.com/healthcare/articles/key-hiv-stat-over-70-140700040.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-08T14:07:00+00:00", "published_display": "08 Aug 2026 14:07", "provider": "eodhd", "providers": ["eodhd"], "source_names": ["finance.yahoo.com"], "source_kind": "aggregator", "story_key": "79772e8de25c5f509e85255edb13d266d3071d862289eabdf1c5a0344dfc1ad0", "target_scope": "", "durable_archive": false, "archive_provider": "", "sentiment_origin": "provider_blend", "model_confidence": 0.776, "provider_directional_mass": 0.092, "relevance_score": 0.45, "entity_mapped": true, "sentiment_conflict": 0.052, "sentiment": "positive", "sentiment_pct": 83, "tone_signals": ["Beat expectations", "Guidance raised", "Improving financial comparison", "Contract or approval won"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.106935, "evidence_share": 8.0, "evidence_share_display": "8", "freshness_pct": 48.8, "age_days": 5.2, "influence_label": "Medium", "duplicate_count": 1, "topics": ["Earnings", "Fda Approval", "Hiv Treatment", "Oncology", "Price Target", "Price Target"], "evidence_basis": "", "score_included": true}, {"title": "Planned 3,000-share sale by Gilead (NASDAQ: GILD) shareholder Johanna Mercier", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22Planned+3%2C000-share+sale+by+Gilead+%28NASDAQ%3A+GILD%29+shareholder+Johanna+Mercier%22+%22Stock+Titan%22", "source_link_is_lookup": true, "source_name": "Stock Titan", "published_at": "2026-08-06T10:28:04.997225+00:00", "published_display": "06 Aug 2026 10:28", "provider": "archive", "providers": ["archive"], "source_names": ["Stock Titan"], "source_kind": "publisher", "story_key": "0b6349ed0ce5671736eacc0242018189b62b18ac58ab4b94d56f301401daf951", "target_scope": "", "durable_archive": true, "archive_provider": "snapshot", "sentiment_origin": "archive_headline", "model_confidence": 0.288, "provider_directional_mass": null, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.003699, "evidence_share": 0.3, "evidence_share_display": "0.3", "freshness_pct": 7.9, "age_days": 7.3, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "Gilead Sciences (GILD) CFO sells 3,000 shares in pre-set 10b5-1 plan", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22Gilead+Sciences+%28GILD%29+CFO+sells+3%2C000+shares+in+pre-set+10b5-1+plan%22+%22Stock+Titan%22", "source_link_is_lookup": true, "source_name": "Stock Titan", "published_at": "2026-08-03T05:29:15.672984+00:00", "published_display": "03 Aug 2026 05:29", "provider": "archive", "providers": ["archive"], "source_names": ["Stock Titan"], "source_kind": "publisher", "story_key": "9c1f21cefb58b24b45e7fe3e30fa65a9dc4c27c82dc0510346e6b891b67d8b1e", "target_scope": "", "durable_archive": true, "archive_provider": "snapshot", "sentiment_origin": "archive_headline", "model_confidence": 0.388, "provider_directional_mass": null, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "negative", "sentiment_pct": 42, "tone_signals": ["Institutional or insider selling"], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.001664, "evidence_share": 0.1, "evidence_share_display": "0.1", "freshness_pct": 2.6, "age_days": 10.5, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "Gilead Sciences (NASDAQ: GILD) exec trades 3,000 shares under 10b5-1 plan", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22Gilead+Sciences+%28NASDAQ%3A+GILD%29+exec+trades+3%2C000+shares+under+10b5-1+plan%22+%22Stock+Titan%22", "source_link_is_lookup": true, "source_name": "Stock Titan", "published_at": "2026-07-30T18:05:24.490652+00:00", "published_display": "30 Jul 2026 18:05", "provider": "archive", "providers": ["archive"], "source_names": ["Stock Titan"], "source_kind": "publisher", "story_key": "4dd55fa093e657035664ca92cb13348d2c2612c3c87df3bacb406fd5e3b61322", "target_scope": "", "durable_archive": true, "archive_provider": "snapshot", "sentiment_origin": "archive_headline", "model_confidence": 0.288, "provider_directional_mass": null, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.000365, "evidence_share": 0.0, "evidence_share_display": "<0.1", "freshness_pct": 0.8, "age_days": 14.0, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "GILD|Gilead Sciences Inc|Price:129.310|Chg%:-1.550", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22GILD%7CGilead+Sciences+Inc%7CPrice%3A129.310%7CChg%25%3A-1.550%22+%22TradingKey%22", "source_link_is_lookup": true, "source_name": "TradingKey", "published_at": "2026-07-28T05:17:20.407677+00:00", "published_display": "28 Jul 2026 05:17", "provider": "archive", "providers": ["archive"], "source_names": ["TradingKey"], "source_kind": "publisher", "story_key": "28134c6376052338fd4e3a7e7d8c4ea2db38262e86b296ecc949f8cd8a5ceae9", "target_scope": "", "durable_archive": true, "archive_provider": "snapshot", "sentiment_origin": "archive_headline", "model_confidence": 0.288, "provider_directional_mass": null, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.000152, "evidence_share": 0.0, "evidence_share_display": "<0.1", "freshness_pct": 0.3, "age_days": 16.5, "influence_label": "Low", "duplicate_count": 2, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "Gilead (NASDAQ: GILD) CEO sells 15,000 shares under 10b5-1 plan", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22Gilead+%28NASDAQ%3A+GILD%29+CEO+sells+15%2C000+shares+under+10b5-1+plan%22+%22Stock+Titan%22", "source_link_is_lookup": true, "source_name": "Stock Titan", "published_at": "2026-07-18T11:27:12.221412+00:00", "published_display": "18 Jul 2026 11:27", "provider": "archive", "providers": ["archive"], "source_names": ["Stock Titan"], "source_kind": "publisher", "story_key": "eeda9bdecb528531bb672a9354b89ff4f7a502ec92a63a7bcb187618904cbe95", "target_scope": "", "durable_archive": true, "archive_provider": "snapshot", "sentiment_origin": "archive_headline", "model_confidence": 0.388, "provider_directional_mass": null, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "negative", "sentiment_pct": 42, "tone_signals": ["Institutional or insider selling"], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 7e-06, "evidence_share": 0.0, "evidence_share_display": "<0.1", "freshness_pct": 0.0, "age_days": 26.3, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "Gilead Sciences (GILD) CFO sells 3,000 shares in pre-set 10b5-1 trade", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22Gilead+Sciences+%28GILD%29+CFO+sells+3%2C000+shares+in+pre-set+10b5-1+trade%22+%22Stock+Titan%22", "source_link_is_lookup": true, "source_name": "Stock Titan", "published_at": "2026-07-17T15:02:55.013921+00:00", "published_display": "17 Jul 2026 15:02", "provider": "archive", "providers": ["archive"], "source_names": ["Stock Titan"], "source_kind": "publisher", "story_key": "80c72f360ec40118ae7159139cf68a01b036e3b49c042c1243433e7e2383ba54", "target_scope": "", "durable_archive": true, "archive_provider": "snapshot", "sentiment_origin": "archive_headline", "model_confidence": 0.388, "provider_directional_mass": null, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "negative", "sentiment_pct": 42, "tone_signals": ["Institutional or insider selling"], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 5e-06, "evidence_share": 0.0, "evidence_share_display": "<0.1", "freshness_pct": 0.0, "age_days": 27.1, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}], "industry": [], "sector": []}, "total_fetched": 27, "total_unique": 19, "total_relevant": 19, "total_matched": 19, "pipeline_health": {"providers_attempted": 1, "providers_with_results": 1, "provider_counts": {"eodhd": 13}, "raw_articles": 27, "unique_stories": 19, "duplicates_removed": 8, "relevant_stories": 19, "matched_archive_stories": 19, "current_evidence": 19, "direct_evidence": 19, "eodhd_articles": 13, "archive_articles": 6, "eodhd": {"configured": true, "status": "healthy", "calls_used": 450, "call_budget": 500, "budget_used_pct": 90.0, "requests_made": 90, "last_success_at": "2026-08-13T18:01:20.695134+00:00", "newest_seen_at": "2026-08-13T17:51:50+00:00", "rate_limit": 1200, "rate_remaining": 1199, "last_error": "", "mapped_mentions": 3123, "unmapped_mentions": 1847}, "status": "healthy"}, "sentiment_summary": {"positive": 7, "negative": 4, "neutral": 8, "score": 57, "raw_score": 61, "total": 19, "evidence_count": 19, "effective_articles": 10.2, "information_mass": 1.333, "direct_story_count": 19, "direct_source_count": 4, "industry_story_count": 0, "sector_story_count": 0, "story_count": 19, "source_count": 4, "source_concentration": 0.9167, "direct_share": 100, "dispersion": 19, "confidence": 46, "evidence_status": "measured", "score_version": "evidence-v7", "window_days": 30, "weighting_method": "event-aware exponential freshness decay", "newest_article_at": "2026-08-13T14:49:26+00:00", "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 77, "events": [{"event": "general", "label": "Market update", "weight": 5.3, "count": 9}, {"event": "earnings", "label": "Earnings", "weight": 2.75, "count": 5}, {"event": "deals", "label": "Deals and strategy", "weight": 1.1, "count": 2}, {"event": "capital_return", "label": "Capital return", "weight": 0.55, "count": 1}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.55, "count": 1}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}], "positive_events": 7, "negative_events": 4, "pipeline": {"providers_attempted": 1, "providers_with_results": 1, "provider_counts": {"eodhd": 13}, "raw_articles": 27, "unique_stories": 19, "duplicates_removed": 8, "relevant_stories": 19, "matched_archive_stories": 19, "current_evidence": 19, "direct_evidence": 19, "eodhd_articles": 13, "archive_articles": 6, "eodhd": {"configured": true, "status": "healthy", "calls_used": 450, "call_budget": 500, "budget_used_pct": 90.0, "requests_made": 90, "last_success_at": "2026-08-13T18:01:20.695134+00:00", "newest_seen_at": "2026-08-13T17:51:50+00:00", "rate_limit": 1200, "rate_remaining": 1199, "last_error": "", "mapped_mentions": 3123, "unmapped_mentions": 1847}, "status": "healthy"}}, "market_context": {"has_market_context": true, "latest_close": 115.7, "latest_week": "2026-08-07", "one_week_move": 2.3, "four_week_move": 0.7, "twelve_week_move": 4.6, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.333979, "market_dynamics_buy_signal": false, "relative_strength": -2.213965, "fair_value_gap": 34.4, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "positive", "expectation_probability": 57.581, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+2.3% over one week, +0.7% over four weeks, trend inactive, and materially above fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 54, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "finance.yahoo.com", "count": 12}, {"label": "Stock Titan", "count": 5}, {"label": "nasdaq.com", "count": 1}, {"label": "TradingKey", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 19}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 9}, {"label": "Earnings", "count": 5}, {"label": "Deals and strategy", "count": 2}, {"label": "Capital return", "count": 1}, {"label": "Regulatory and legal", "count": 1}, {"label": "Guidance", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "57/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Evidence confidence", "value": "46/100", "tone": "neutral", "text": "10.2 effective stories after overlap and weighting."}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "77/100 evidence concentration around this catalyst."}, {"label": "Company focus", "value": "19", "tone": "positive", "text": "100% of weighted evidence is company-specific."}, {"label": "Evidence agreement", "value": "19/100", "tone": "neutral", "text": "lower dispersion means the independent stories agree more closely."}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+2.3% over one week, +0.7% over four weeks, trend inactive, and materially above fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Noteworthy ETF Outflows: TQQQ, ADI, MRVL, GILD"}], "updated_at": "2026-08-13T18:11:48.584361+00:00", "detail_intelligence": {"headline": "Balanced news tone", "summary": "The score uses 19 current company stories from 4 publishers.", "status": "measured", "metrics": [{"label": "News score", "value": 57, "display": "57", "tone": "neutral", "note": "Balanced news tone"}, {"label": "Confidence", "value": 46, "display": "46", "tone": "neutral", "note": "building confidence"}, {"label": "Company news", "value": 100, "display": "100%", "tone": "positive", "note": "19 company stories"}, {"label": "Story agreement", "value": 81, "display": "81", "tone": "positive", "note": "19/100 difference"}], "confidence_drivers": [{"label": "Amount of evidence", "value": 27, "note": "1.333 after freshness weighting"}, {"label": "Source breadth", "value": 80, "note": "4 independent publishers"}, {"label": "Company relevance", "value": 100, "note": "share tied directly to this company"}, {"label": "Freshness", "value": 75, "note": "recency-weighted evidence"}, {"label": "Agreement", "value": 81, "note": "how closely stories agree"}, {"label": "Publisher mix", "value": 8, "note": "less reliance on one publisher"}], "freshness": 75, "source_independence": 8, "timeline": [{"date": "2026-07-15", "label": "15 Jul", "count": 0, "score": null, "tone": "neutral", "x": 42.0, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-16", "label": "16 Jul", "count": 0, "score": null, "tone": "neutral", "x": 73.6, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-17", "label": "17 Jul", "count": 1, "score": 42, "tone": "negative", "x": 105.2, "y": 149.6, "volume_height": 10.4, "volume_y": 255.6}, {"date": "2026-07-18", "label": "18 Jul", "count": 1, "score": 42, "tone": "negative", "x": 136.8, "y": 149.6, "volume_height": 10.4, "volume_y": 255.6}, {"date": "2026-07-19", "label": "19 Jul", "count": 0, "score": null, "tone": "neutral", "x": 168.3, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-20", "label": "20 Jul", "count": 0, "score": null, "tone": "neutral", "x": 199.9, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-21", "label": "21 Jul", "count": 0, "score": null, "tone": "neutral", "x": 231.5, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-22", "label": "22 Jul", "count": 0, "score": null, "tone": "neutral", "x": 263.1, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-23", "label": "23 Jul", "count": 0, "score": null, "tone": "neutral", "x": 294.7, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-24", "label": "24 Jul", "count": 0, "score": null, "tone": "neutral", "x": 326.3, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-25", "label": "25 Jul", "count": 0, "score": null, "tone": "neutral", "x": 357.9, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-26", "label": "26 Jul", "count": 0, "score": null, "tone": "neutral", "x": 389.4, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-27", "label": "27 Jul", "count": 0, "score": null, "tone": "neutral", "x": 421.0, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-28", "label": "28 Jul", "count": 1, "score": 50, "tone": "neutral", "x": 452.6, "y": 135.0, "volume_height": 10.4, "volume_y": 255.6}, {"date": "2026-07-29", "label": "29 Jul", "count": 0, "score": null, "tone": "neutral", "x": 484.2, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-30", "label": "30 Jul", "count": 1, "score": 50, "tone": "neutral", "x": 515.8, "y": 135.0, "volume_height": 10.4, "volume_y": 255.6}, {"date": "2026-07-31", "label": "31 Jul", "count": 0, "score": null, "tone": "neutral", "x": 547.4, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-01", "label": "01 Aug", "count": 0, "score": null, "tone": "neutral", "x": 579.0, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-02", "label": "02 Aug", "count": 0, "score": null, "tone": "neutral", "x": 610.6, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-03", "label": "03 Aug", "count": 1, "score": 42, "tone": "negative", "x": 642.1, "y": 149.6, "volume_height": 10.4, "volume_y": 255.6}, {"date": "2026-08-04", "label": "04 Aug", "count": 0, "score": null, "tone": "neutral", "x": 673.7, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-05", "label": "05 Aug", "count": 0, "score": null, "tone": "neutral", "x": 705.3, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-06", "label": "06 Aug", "count": 1, "score": 50, "tone": "neutral", "x": 736.9, "y": 135.0, "volume_height": 10.4, "volume_y": 255.6}, {"date": "2026-08-07", "label": "07 Aug", "count": 0, "score": null, "tone": "neutral", "x": 768.5, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-08", "label": "08 Aug", "count": 1, "score": 83, "tone": "positive", "x": 800.1, "y": 74.9, "volume_height": 10.4, "volume_y": 255.6}, {"date": "2026-08-09", "label": "09 Aug", "count": 0, "score": null, "tone": "neutral", "x": 831.7, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-10", "label": "10 Aug", "count": 1, "score": 54, "tone": "neutral", "x": 863.2, "y": 127.7, "volume_height": 10.4, "volume_y": 255.6}, {"date": "2026-08-11", "label": "11 Aug", "count": 5, "score": 66, "tone": "positive", "x": 894.8, "y": 105.9, "volume_height": 52.0, "volume_y": 214.0}, {"date": "2026-08-12", "label": "12 Aug", "count": 3, "score": 50, "tone": "neutral", "x": 926.4, "y": 135.0, "volume_height": 31.2, "volume_y": 234.8}, {"date": "2026-08-13", "label": "13 Aug", "count": 3, "score": 67, "tone": "positive", "x": 958.0, "y": 104.1, "volume_height": 31.2, "volume_y": 234.8}], "timeline_points": "105.2,149.6 136.8,149.6 452.6,135.0 515.8,135.0 642.1,149.6 736.9,135.0 800.1,74.9 863.2,127.7 894.8,105.9 926.4,135.0 958.0,104.1", "timeline_has_signal": true, "timeline_start": "15 Jul", "timeline_mid": "30 Jul", "timeline_end": "13 Aug", "momentum": {"label": "Tentative cooling", "tone": "neutral", "recent_score": 59, "prior_score": 83, "delta": -24, "recent_count": 12, "prior_count": 1, "volume_delta": 11, "reliable": false, "reliability_note": "Thin comparison; direction is not yet confirmed"}, "freshness_buckets": [{"label": "Last 24 hours", "count": 4, "share": 21}, {"label": "1 to 3 days", "count": 8, "share": 42}, {"label": "4 to 7 days", "count": 1, "share": 5}, {"label": "8 to 14 days", "count": 2, "share": 11}, {"label": "15 to 21 days", "count": 2, "share": 11}, {"label": "22 to 30 days", "count": 2, "share": 11}], "source_profile": [{"label": "finance.yahoo.com", "count": 12, "share": 63, "score": 62, "tone": "positive"}, {"label": "Stock Titan", "count": 5, "share": 26, "score": 48, "tone": "neutral"}, {"label": "nasdaq.com", "count": 1, "share": 5, "score": 53, "tone": "neutral"}, {"label": "TradingKey", "count": 1, "share": 5, "score": 50, "tone": "neutral"}], "event_profile": [{"label": "Market update", "count": 9, "share": 47, "score": 54, "tone": "neutral"}, {"label": "Earnings", "count": 5, "share": 26, "score": 64, "tone": "positive"}, {"label": "Deals and strategy", "count": 2, "share": 11, "score": 64, "tone": "positive"}, {"label": "Regulatory and legal", "count": 1, "share": 5, "score": 62, "tone": "positive"}, {"label": "Capital return", "count": 1, "share": 5, "score": 46, "tone": "neutral"}, {"label": "Guidance", "count": 1, "share": 5, "score": 50, "tone": "neutral"}], "topics": [{"label": "Earnings", "count": 6, "share": 32}, {"label": "Biotech", "count": 6, "share": 32}, {"label": "EARNINGS", "count": 4, "share": 21}, {"label": "BIOTECH", "count": 4, "share": 21}, {"label": "Oncology", "count": 3, "share": 16}, {"label": "Fda Approval", "count": 3, "share": 16}, {"label": "Share Price", "count": 2, "share": 11}, {"label": "Price Target", "count": 2, "share": 11}, {"label": "Pharmaceuticals", "count": 2, "share": 11}, {"label": "EARNINGS PER SHARE", "count": 2, "share": 11}], "supporting": [{"label": "Direct evidence", "text": "19 current stories are mapped specifically to GIS."}, {"label": "Source breadth", "text": "The read spans 4 publishers rather than depending on one outlet."}, {"label": "Story agreement", "text": "The current stories agree at 81/100."}], "tempering": [], "supporting_heading": "What supports the score", "tempering_heading": "What limits the score", "latest_observation": {"title": "Noteworthy ETF Outflows: TQQQ, ADI, MRVL, GILD", "summary": "Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the ProShares UltraPro QQQ (Symbol: TQQQ) where we have detected an approximate $156.7 million dollar outflow -- that's a 0.4% decrease week over week (from 506,050,000 to 503,950,000). Among the largest underlying components of TQQQ, in trading today Analog Devices Inc (Symbol: ADI) is up about 0.8%, Marvell Technology Inc (Symbol: MRVL) is up about 4.9%, and Gilead Sciences Inc (Symbol: GILD) is up by about 1%. For a complete list of holdings, visit the TQQQ Holdings ", "url": "https://www.nasdaq.com/articles/noteworthy-etf-outflows-tqqq-adi-mrvl-gild", "source_link": "https://www.nasdaq.com/articles/noteworthy-etf-outflows-tqqq-adi-mrvl-gild", "source_link_is_lookup": false, "source_name": "nasdaq.com", "published_at": "2026-08-13T14:49:26+00:00", "published_display": "13 Aug 2026 14:49", "source_kind": "publisher", "sentiment": "neutral", "sentiment_pct": 53, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.051909, "evidence_share": 3.9, "evidence_share_display": "3.9", "freshness_pct": 95.2, "age_days": 0.1, "influence_label": "Low", "duplicate_count": 1, "topics": ["ETF", "Etfs", "Markets", "Semiconductors", "Share Price", "Shares Outstanding"], "evidence_basis": "", "score_included": true}, "article_count": 19, "updated_at": "2026-08-13T18:11:48.584361+00:00"}, "price_sentiment_path": {"available": true, "price_points": [{"x": 42.0, "y": 55.8, "label": "13 Feb 2026", "close": 129.32, "index": 100.0}, {"x": 78.4, "y": 71.2, "label": "20 Feb 2026", "close": 126.99, "index": 98.2}, {"x": 114.9, "y": 92.7, "label": "27 Feb 2026", "close": 123.72, "index": 95.7}, {"x": 151.3, "y": 102.5, "label": "06 Mar 2026", "close": 122.24, "index": 94.5}, {"x": 187.7, "y": 77.5, "label": "13 Mar 2026", "close": 126.03, "index": 97.5}, {"x": 224.2, "y": 129.6, "label": "20 Mar 2026", "close": 118.13, "index": 91.4}, {"x": 260.6, "y": 134.4, "label": "27 Mar 2026", "close": 117.4, "index": 90.8}, {"x": 297.0, "y": 114.6, "label": "03 Apr 2026", "close": 120.4, "index": 93.1}, {"x": 333.5, "y": 125.4, "label": "10 Apr 2026", "close": 118.77, "index": 91.8}, {"x": 369.9, "y": 143.4, "label": "17 Apr 2026", "close": 116.03, "index": 89.7}, {"x": 406.3, "y": 178.9, "label": "24 Apr 2026", "close": 110.65, "index": 85.6}, {"x": 442.8, "y": 173.3, "label": "01 May 2026", "close": 111.5, "index": 86.2}, {"x": 479.2, "y": 182.3, "label": "08 May 2026", "close": 110.13, "index": 85.2}, {"x": 515.6, "y": 179.5, "label": "15 May 2026", "close": 110.57, "index": 85.5}, {"x": 552.0, "y": 158.4, "label": "22 May 2026", "close": 113.77, "index": 88.0}, {"x": 588.5, "y": 153.3, "label": "29 May 2026", "close": 114.54, "index": 88.6}, {"x": 624.9, "y": 167.1, "label": "05 Jun 2026", "close": 112.44, "index": 86.9}, {"x": 661.3, "y": 204.2, "label": "12 Jun 2026", "close": 106.82, "index": 82.6}, {"x": 697.8, "y": 196.3, "label": "19 Jun 2026", "close": 108.02, "index": 83.5}, {"x": 734.2, "y": 174.5, "label": "26 Jun 2026", "close": 111.32, "index": 86.1}, {"x": 770.6, "y": 158.2, "label": "03 Jul 2026", "close": 113.8, "index": 88.0}, {"x": 807.1, "y": 151.2, "label": "10 Jul 2026", "close": 114.86, "index": 88.8}, {"x": 843.5, "y": 114.0, "label": "17 Jul 2026", "close": 120.5, "index": 93.2}, {"x": 879.9, "y": 155.4, "label": "24 Jul 2026", "close": 114.22, "index": 88.3}, {"x": 916.4, "y": 163.0, "label": "31 Jul 2026", "close": 113.06, "index": 87.4}, {"x": 952.8, "y": 145.6, "label": "07 Aug 2026", "close": 115.7, "index": 89.5}], "sentiment_points": [{"at": "2026-06-26T23:59:59.999Z", "date": "2026-06-26", "label": "26 Jun 2026", "score": 50, "tone": "neutral", "raw_score": 50, "confidence": 17, "stories": 2, "close": 111.32, "price_change": 3.1, "x": 739.4, "y": 130.0, "show_label": true, "label_y": 120.0}, {"at": "2026-07-03T23:59:59.999Z", "date": "2026-07-03", "label": "03 Jul 2026", "score": 50, "tone": "neutral", "raw_score": 52, "confidence": 23, "stories": 4, "close": 113.8, "price_change": 2.2, "x": 775.8, "y": 130.0, "show_label": true, "label_y": 120.0}, {"at": "2026-07-10T23:59:59.999Z", "date": "2026-07-10", "label": "10 Jul 2026", "score": 50, "tone": "neutral", "raw_score": 50, "confidence": 17, "stories": 5, "close": 114.86, "price_change": 0.9, "x": 812.3, "y": 130.0, "show_label": true, "label_y": 120.0}, {"at": "2026-07-17T23:59:59.999Z", "date": "2026-07-17", "label": "17 Jul 2026", "score": 49, "tone": "neutral", "raw_score": 42, "confidence": 28, "stories": 6, "close": 120.5, "price_change": 4.9, "x": 848.7, "y": 131.8, "show_label": true, "label_y": 121.80000000000001}, {"at": "2026-07-24T23:59:59.999Z", "date": "2026-07-24", "label": "24 Jul 2026", "score": 50, "tone": "neutral", "raw_score": 42, "confidence": 16, "stories": 5, "close": 114.22, "price_change": -5.2, "x": 885.1, "y": 130.0, "show_label": true, "label_y": 120.0}, {"at": "2026-07-31T23:59:59.999Z", "date": "2026-07-31", "label": "31 Jul 2026", "score": 50, "tone": "neutral", "raw_score": 50, "confidence": 22, "stories": 6, "close": 113.06, "price_change": -1.0, "x": 921.6, "y": 130.0, "show_label": true, "label_y": 120.0}, {"at": "2026-08-07T23:59:59.999Z", "date": "2026-08-07", "label": "07 Aug 2026", "score": 50, "tone": "neutral", "raw_score": 48, "confidence": 21, "stories": 6, "close": 115.7, "price_change": 2.3, "x": 958.0, "y": 130.0, "show_label": true, "label_y": 120.0}], "price_path": "42.0,55.8 78.4,71.2 114.9,92.7 151.3,102.5 187.7,77.5 224.2,129.6 260.6,134.4 297.0,114.6 333.5,125.4 369.9,143.4 406.3,178.9 442.8,173.3 479.2,182.3 515.6,179.5 552.0,158.4 588.5,153.3 624.9,167.1 661.3,204.2 697.8,196.3 734.2,174.5 770.6,158.2 807.1,151.2 843.5,114.0 879.9,155.4 916.4,163.0 952.8,145.6", "sentiment_path": "739.4,130.0 775.8,130.0 812.3,130.0 848.7,131.8 885.1,130.0 921.6,130.0 958.0,130.0", "score_version": "evidence-v7", "price_change": -10.5, "sentiment_change": 0, "recent_pairs": [{"at": "2026-08-07T23:59:59.999Z", "date": "2026-08-07", "label": "07 Aug 2026", "score": 50, "tone": "neutral", "raw_score": 48, "confidence": 21, "stories": 6, "close": 115.7, "price_change": 2.3, "x": 958.0, "y": 130.0, "show_label": true, "label_y": 120.0}, {"at": "2026-07-31T23:59:59.999Z", "date": "2026-07-31", "label": "31 Jul 2026", "score": 50, "tone": "neutral", "raw_score": 50, "confidence": 22, "stories": 6, "close": 113.06, "price_change": -1.0, "x": 921.6, "y": 130.0, "show_label": true, "label_y": 120.0}, {"at": "2026-07-24T23:59:59.999Z", "date": "2026-07-24", "label": "24 Jul 2026", "score": 50, "tone": "neutral", "raw_score": 42, "confidence": 16, "stories": 5, "close": 114.22, "price_change": -5.2, "x": 885.1, "y": 130.0, "show_label": true, "label_y": 120.0}, {"at": "2026-07-17T23:59:59.999Z", "date": "2026-07-17", "label": "17 Jul 2026", "score": 49, "tone": "neutral", "raw_score": 42, "confidence": 28, "stories": 6, "close": 120.5, "price_change": 4.9, "x": 848.7, "y": 131.8, "show_label": true, "label_y": 121.80000000000001}, {"at": "2026-07-10T23:59:59.999Z", "date": "2026-07-10", "label": "10 Jul 2026", "score": 50, "tone": "neutral", "raw_score": 50, "confidence": 17, "stories": 5, "close": 114.86, "price_change": 0.9, "x": 812.3, "y": 130.0, "show_label": true, "label_y": 120.0}, {"at": "2026-07-03T23:59:59.999Z", "date": "2026-07-03", "label": "03 Jul 2026", "score": 50, "tone": "neutral", "raw_score": 52, "confidence": 23, "stories": 4, "close": 113.8, "price_change": 2.2, "x": 775.8, "y": 130.0, "show_label": true, "label_y": 120.0}, {"at": "2026-06-26T23:59:59.999Z", "date": "2026-06-26", "label": "26 Jun 2026", "score": 50, "tone": "neutral", "raw_score": 50, "confidence": 17, "stories": 2, "close": 111.32, "price_change": 3.1, "x": 739.4, "y": 130.0, "show_label": true, "label_y": 120.0}], "reconstructed": true, "latest_close": 115.7, "start_label": "13 Feb", "mid_label": "15 May", "end_label": "07 Aug", "live_score_version": "evidence-v7", "comparable_to_live": true}, "sentiment_history": [{"label": "22 Jun 23:59", "short_label": "22 Jun", "collected_at": "2026-06-22T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": null, "score_change_display": "Start", "confidence_change": null, "article_change": null, "tone": "neutral", "height": 4, "articles": 2, "confidence": 27, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "27 Jun 23:59", "short_label": "27 Jun", "collected_at": "2026-06-27T23:59:59.999999+00:00", "score": 51, "delta": 1, "score_change": 1, "score_change_display": "+1", "confidence_change": -2, "article_change": 1, "tone": "neutral", "height": 4, "articles": 3, "confidence": 25, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "02 Jul 23:59", "short_label": "02 Jul", "collected_at": "2026-07-02T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": -1, "score_change_display": "-1", "confidence_change": 1, "article_change": 1, "tone": "neutral", "height": 4, "articles": 4, "confidence": 26, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "07 Jul 23:59", "short_label": "07 Jul", "collected_at": "2026-07-07T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": -2, "article_change": 1, "tone": "neutral", "height": 4, "articles": 5, "confidence": 24, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "17 Jul 23:59", "short_label": "17 Jul", "collected_at": "2026-07-17T23:59:59.999999+00:00", "score": 49, "delta": -1, "score_change": -1, "score_change_display": "-1", "confidence_change": 4, "article_change": 1, "tone": "neutral", "height": 4, "articles": 6, "confidence": 28, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "18 Jul 23:59", "short_label": "18 Jul", "collected_at": "2026-07-18T23:59:59.999999+00:00", "score": 49, "delta": -1, "score_change": 0, "score_change_display": "+0", "confidence_change": -1, "article_change": 1, "tone": "neutral", "height": 4, "articles": 7, "confidence": 27, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "28 Jul 23:59", "short_label": "28 Jul", "collected_at": "2026-07-28T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 1, "score_change_display": "+1", "confidence_change": -2, "article_change": -2, "tone": "neutral", "height": 4, "articles": 5, "confidence": 25, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "30 Jul 23:59", "short_label": "30 Jul", "collected_at": "2026-07-30T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": 1, "article_change": 1, "tone": "neutral", "height": 4, "articles": 6, "confidence": 26, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "03 Aug 23:59", "short_label": "03 Aug", "collected_at": "2026-08-03T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": -1, "article_change": 0, "tone": "neutral", "height": 4, "articles": 6, "confidence": 25, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "06 Aug 23:59", "short_label": "06 Aug", "collected_at": "2026-08-06T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": -1, "article_change": 0, "tone": "neutral", "height": 4, "articles": 6, "confidence": 24, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "08 Aug 23:59", "short_label": "08 Aug", "collected_at": "2026-08-08T23:59:59.999999+00:00", "score": 57, "delta": 7, "score_change": 7, "score_change_display": "+7", "confidence_change": 7, "article_change": 1, "tone": "neutral", "height": 14, "articles": 7, "confidence": 31, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "10 Aug 23:59", "short_label": "10 Aug", "collected_at": "2026-08-10T23:59:59.999999+00:00", "score": 54, "delta": 4, "score_change": -3, "score_change_display": "-3", "confidence_change": -3, "article_change": 1, "tone": "neutral", "height": 8, "articles": 8, "confidence": 28, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "11 Aug 23:59", "short_label": "11 Aug", "collected_at": "2026-08-11T23:59:59.999999+00:00", "score": 57, "delta": 7, "score_change": 3, "score_change_display": "+3", "confidence_change": 9, "article_change": 5, "tone": "neutral", "height": 14, "articles": 13, "confidence": 37, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "12 Aug 23:59", "short_label": "12 Aug", "collected_at": "2026-08-12T23:59:59.999999+00:00", "score": 53, "delta": 3, "score_change": -4, "score_change_display": "-4", "confidence_change": 6, "article_change": 3, "tone": "neutral", "height": 6, "articles": 16, "confidence": 43, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v7", "reconstructed": true}, {"label": "13 Aug 18:11", "short_label": "13 Aug", "collected_at": "2026-08-13T18:11:48.593248+00:00", "score": 55, "delta": 5, "score_change": 2, "score_change_display": "+2", "confidence_change": 1, "article_change": 3, "tone": "neutral", "height": 10, "articles": 19, "confidence": 44, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v7", "reconstructed": true}], "sentiment_history_insight": {"available": true, "series_version": "evidence-v7", "live_version": "evidence-v7", "comparable_to_live": true, "reconstructed": true, "observations": 15, "span_label": "52 days", "first_score": 50, "latest_score": 55, "net_change": 5, "net_change_display": "+5", "direction": "Strengthening", "high_score": 57, "low_score": 49, "latest_confidence": 44, "confidence_change": 17, "latest_articles": 19, "article_change": 17, "latest_label": "13 Aug 18:11", "latest_evidence_label": "Measured", "chart_rows": [{"label": "22 Jun 23:59", "short_label": "22 Jun", "collected_at": "2026-06-22T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": null, "score_change_display": "Start", "confidence_change": null, "article_change": null, "tone": "neutral", "height": 4, "articles": 2, "confidence": 27, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 42.0, "y": 135.0}, {"label": "27 Jun 23:59", "short_label": "27 Jun", "collected_at": "2026-06-27T23:59:59.999999+00:00", "score": 51, "delta": 1, "score_change": 1, "score_change_display": "+1", "confidence_change": -2, "article_change": 1, "tone": "neutral", "height": 4, "articles": 3, "confidence": 25, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 107.4, "y": 133.2}, {"label": "02 Jul 23:59", "short_label": "02 Jul", "collected_at": "2026-07-02T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": -1, "score_change_display": "-1", "confidence_change": 1, "article_change": 1, "tone": "neutral", "height": 4, "articles": 4, "confidence": 26, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 172.9, "y": 135.0}, {"label": "07 Jul 23:59", "short_label": "07 Jul", "collected_at": "2026-07-07T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": -2, "article_change": 1, "tone": "neutral", "height": 4, "articles": 5, "confidence": 24, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 238.3, "y": 135.0}, {"label": "17 Jul 23:59", "short_label": "17 Jul", "collected_at": "2026-07-17T23:59:59.999999+00:00", "score": 49, "delta": -1, "score_change": -1, "score_change_display": "-1", "confidence_change": 4, "article_change": 1, "tone": "neutral", "height": 4, "articles": 6, "confidence": 28, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 303.7, "y": 136.8}, {"label": "18 Jul 23:59", "short_label": "18 Jul", "collected_at": "2026-07-18T23:59:59.999999+00:00", "score": 49, "delta": -1, "score_change": 0, "score_change_display": "+0", "confidence_change": -1, "article_change": 1, "tone": "neutral", "height": 4, "articles": 7, "confidence": 27, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 369.1, "y": 136.8}, {"label": "28 Jul 23:59", "short_label": "28 Jul", "collected_at": "2026-07-28T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 1, "score_change_display": "+1", "confidence_change": -2, "article_change": -2, "tone": "neutral", "height": 4, "articles": 5, "confidence": 25, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 434.6, "y": 135.0}, {"label": "30 Jul 23:59", "short_label": "30 Jul", "collected_at": "2026-07-30T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": 1, "article_change": 1, "tone": "neutral", "height": 4, "articles": 6, "confidence": 26, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 500.0, "y": 135.0}, {"label": "03 Aug 23:59", "short_label": "03 Aug", "collected_at": "2026-08-03T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": -1, "article_change": 0, "tone": "neutral", "height": 4, "articles": 6, "confidence": 25, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 565.4, "y": 135.0}, {"label": "06 Aug 23:59", "short_label": "06 Aug", "collected_at": "2026-08-06T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": -1, "article_change": 0, "tone": "neutral", "height": 4, "articles": 6, "confidence": 24, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 630.9, "y": 135.0}, {"label": "08 Aug 23:59", "short_label": "08 Aug", "collected_at": "2026-08-08T23:59:59.999999+00:00", "score": 57, "delta": 7, "score_change": 7, "score_change_display": "+7", "confidence_change": 7, "article_change": 1, "tone": "neutral", "height": 14, "articles": 7, "confidence": 31, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 696.3, "y": 122.3}, {"label": "10 Aug 23:59", "short_label": "10 Aug", "collected_at": "2026-08-10T23:59:59.999999+00:00", "score": 54, "delta": 4, "score_change": -3, "score_change_display": "-3", "confidence_change": -3, "article_change": 1, "tone": "neutral", "height": 8, "articles": 8, "confidence": 28, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 761.7, "y": 127.7}, {"label": "11 Aug 23:59", "short_label": "11 Aug", "collected_at": "2026-08-11T23:59:59.999999+00:00", "score": 57, "delta": 7, "score_change": 3, "score_change_display": "+3", "confidence_change": 9, "article_change": 5, "tone": "neutral", "height": 14, "articles": 13, "confidence": 37, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 827.1, "y": 122.3}, {"label": "12 Aug 23:59", "short_label": "12 Aug", "collected_at": "2026-08-12T23:59:59.999999+00:00", "score": 53, "delta": 3, "score_change": -4, "score_change_display": "-4", "confidence_change": 6, "article_change": 3, "tone": "neutral", "height": 6, "articles": 16, "confidence": 43, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v7", "reconstructed": true, "x": 892.6, "y": 129.5}, {"label": "13 Aug 18:11", "short_label": "13 Aug", "collected_at": "2026-08-13T18:11:48.593248+00:00", "score": 55, "delta": 5, "score_change": 2, "score_change_display": "+2", "confidence_change": 1, "article_change": 3, "tone": "neutral", "height": 10, "articles": 19, "confidence": 44, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v7", "reconstructed": true, "x": 958.0, "y": 125.9}], "chart_points": "42.0,135.0 107.4,133.2 172.9,135.0 238.3,135.0 303.7,136.8 369.1,136.8 434.6,135.0 500.0,135.0 565.4,135.0 630.9,135.0 696.3,122.3 761.7,127.7 827.1,122.3 892.6,129.5 958.0,125.9", "changes": [{"label": "13 Aug 18:11", "short_label": "13 Aug", "collected_at": "2026-08-13T18:11:48.593248+00:00", "score": 55, "delta": 5, "score_change": 2, "score_change_display": "+2", "confidence_change": 1, "article_change": 3, "tone": "neutral", "height": 10, "articles": 19, "confidence": 44, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v7", "reconstructed": true}, {"label": "12 Aug 23:59", "short_label": "12 Aug", "collected_at": "2026-08-12T23:59:59.999999+00:00", "score": 53, "delta": 3, "score_change": -4, "score_change_display": "-4", "confidence_change": 6, "article_change": 3, "tone": "neutral", "height": 6, "articles": 16, "confidence": 43, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v7", "reconstructed": true}, {"label": "11 Aug 23:59", "short_label": "11 Aug", "collected_at": "2026-08-11T23:59:59.999999+00:00", "score": 57, "delta": 7, "score_change": 3, "score_change_display": "+3", "confidence_change": 9, "article_change": 5, "tone": "neutral", "height": 14, "articles": 13, "confidence": 37, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "10 Aug 23:59", "short_label": "10 Aug", "collected_at": "2026-08-10T23:59:59.999999+00:00", "score": 54, "delta": 4, "score_change": -3, "score_change_display": "-3", "confidence_change": -3, "article_change": 1, "tone": "neutral", "height": 8, "articles": 8, "confidence": 28, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "08 Aug 23:59", "short_label": "08 Aug", "collected_at": "2026-08-08T23:59:59.999999+00:00", "score": 57, "delta": 7, "score_change": 7, "score_change_display": "+7", "confidence_change": 7, "article_change": 1, "tone": "neutral", "height": 14, "articles": 7, "confidence": 31, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "06 Aug 23:59", "short_label": "06 Aug", "collected_at": "2026-08-06T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": -1, "article_change": 0, "tone": "neutral", "height": 4, "articles": 6, "confidence": 24, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "03 Aug 23:59", "short_label": "03 Aug", "collected_at": "2026-08-03T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": -1, "article_change": 0, "tone": "neutral", "height": 4, "articles": 6, "confidence": 25, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "30 Jul 23:59", "short_label": "30 Jul", "collected_at": "2026-07-30T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": 1, "article_change": 1, "tone": "neutral", "height": 4, "articles": 6, "confidence": 26, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}]}, "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}